ImmunityBio Stock Surges 30% on Anktiva Revenue Beat and Regulatory Approvals
ImmunityBio shares skyrocketed more than 30% Thursday after reporting explosive growth for its cancer immunotherapy Anktiva. Preliminary 2025 results showed revenue jumping nearly 700% year-over-year to $113 million, with Q4 sales hitting $38.3 million - a 431% increase from 2024 levels.
The Saudi FDA's approval for metastatic lung cancer treatment marked a watershed moment, representing Anktiva's first global clearance for this indication. Additional approvals in bladder cancer expanded the drug's addressable markets across the U.S., U.K., and EU regions.
Trading volume spiked to 70.4 million shares, exceeding the three-month average by 442%. Wall Street maintains strong conviction with an average $7.33 price target suggesting 85% upside potential from current levels.
